Phase 3 INTerpath-001 Trial Shows Promise for Melanoma Treatment
New data from the INTerpath-001 trial indicates that combining intismeran autogene with pembrolizumab may enhance survival rates in melanoma patients.
The INTerpath-001 trial demonstrated improved recurrence-free survival in melanoma patients.
Intismeran autogene, an mRNA-based therapy, shows potential as a personalized treatment.
Tumor-infiltrating lymphocyte therapy may be beneficial in earlier treatment lines.
Recent findings from the phase 3 INTerpath-001 trial reveal that the combination of intismeran autogene and pembrolizumab significantly enhances recurrence-free survival in patients with resected stage IIB to IV melanoma. This trial, presented at the European Society for Medical Oncology (ESMO) Congress, involved a randomized, double-blind design and included 1,089 participants who had undergone surgical resection for melanoma.
The INTerpath-001 study, sponsored by Merck Sharp & Dohme LLC in partnership with ModernaTX, Inc., aims to assess the efficacy of the personalized mRNA-based neoantigen therapy, intismeran autogene (V940), alongside pembrolizumab (Keytruda). The primary endpoint focuses on recurrence-free survival (RFS), while secondary endpoints evaluate distant metastasis-free survival, overall survival, safety, and quality of life. Eligible participants were aged 18 and older, with no prior systemic therapy for melanoma.
Dr. Karam Khaddour, a medical oncologist at Dana-Farber Cancer Institute, emphasized the importance of personalized treatment approaches in melanoma care. He noted that the integration of intismeran autogene into treatment regimens could represent a significant advancement in improving patient outcomes. The results suggest that personalized cancer vaccines can play a crucial role in adjuvant therapy settings.
In addition to the intismeran findings, the trial also explored the potential of tumor-infiltrating lymphocyte (TIL) therapy in earlier treatment lines. Currently approved for patients resistant to anti–PD-1 therapy, TIL therapy demonstrated promising results in a small cohort study, achieving a 60% objective response rate and a 30% complete response rate. These findings indicate that TIL therapy could be effectively utilized before patients become more treatment-resistant.
Looking ahead, the ongoing research into both intismeran autogene and TIL therapy may reshape treatment strategies for melanoma. The INTerpath-001 trial continues to gather data, and further studies are anticipated to validate these findings and explore the broader implications for melanoma treatment protocols.




